OPTIMAL PROPHYLACTIC PLATELET DOSE STRATEGY / THROMOCYTOPENIC PATIENTS

最佳预防性血小板剂量策略/血小板减少症患者

• 批准号: 7380753
• 负责人: STEVEN R SLOAN
• 金额: $ 7.38万
• 依托单位: BOSTON CHILDREN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7380753
• 关键词: OPTIMAL; PROPHYLACTIC; PLATELET; DOSE; STRATEGY

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. To compare the three study arms of medium, lower, and higher dose platelet therapy with respect to the percentage of patients experiencing at least one episode of Grade 2 or higher bleeding as determined by the Platelet Dose Trial Bleeding Scale.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。比较中等、较低和较高剂量血小板治疗的3个研究组中至少发生1次2级或2级以上出血事件（根据血小板剂量试验出血量表确定）的患者百分比。